ChemLifeIntel
Access
CLINICAL & PIPELINEDrug ApprovalNotable

Sun Pharma Canada Secures FDA Approval for Generic Clobetasol Propionate Spray: Market Impact and Procurement Shifts

PS
Priya SubramaniamView Profile →
Intelligence Analyst
EXECUTIVE SUMMARY

Sun Pharma Canada has received FDA approval for its generic Clobetasol Propionate 0.05% Topical Spray (ANDA208842) on March 26, 2018. This development introduces a new therapeutically equivalent option into the market, intensifying competition for existing suppliers. Procurement directors and supply chain VPs must now re-evaluate sourcing strategies to capitalize on potential cost efficiencies and enhance supply chain resilience.

Approval Summary: Generic Clobetasol Propionate Spray by Sun Pharma Canada

On March 26, 2018, Sun Pharma Canada, with manufacturing attributed to Sun Pharmaceutical Industries, Inc., secured a significant regulatory milestone with the U.S. Food and Drug Administration (FDA) approval of its Abbreviated New Drug Application (ANDA208842) for Clobetasol Propionate 0.05% Topical Spray. This approval introduces a new generic formulation of a potent corticosteroid widely utilized in dermatology. The product is designated with a 'STANDARD' review priority, indicating a typical regulatory pathway without expedited status. For procurement directors and business development executives, this means a new, therapeutically equivalent option is now available on the market, directly impacting the competitive landscape for Clobetasol Propionate. The approval of this generic spray formulation, identified by product NDC 51672-1371, signifies an immediate opportunity to reassess existing supply agreements and potentially negotiate more favorable terms. Regulatory affairs heads should note the 'AT' therapeutic equivalence code, confirming its bioequivalence and interchangeability with the reference product, which facilitates rapid market adoption and integration into formularies.

Market Dynamics: Erosion and Pricing After Generic Clobetasol Propionate Entry

The entry of Sun Pharma Canada's generic Clobetasol Propionate 0.05% Topical Spray into the market will inevitably trigger significant shifts in market dynamics, particularly concerning pricing and market share. For companies currently supplying Clobetasol Propionate, this development signals an immediate and sustained pressure on pricing. Generic competition typically leads to rapid price erosion, often commencing within weeks of market entry, as manufacturers vie for formulary positions and market penetration. Procurement directors should leverage this increased competition to drive down acquisition costs for this critical dermatological agent. Supply chain VPs must anticipate potential changes in demand patterns as healthcare providers and payers shift towards the more cost-effective generic alternative. Business development executives need to recalibrate their sales forecasts and market strategies for Clobetasol Propionate, acknowledging that market share for branded or existing generic versions will likely face erosion. The availability of a new, 'AT'-rated generic product from a major player like Sun Pharma Canada ensures that this competitive pressure will be substantial and sustained, necessitating agile responses from all market participants.

Competitive Landscape: Implications for Clobetasol Propionate Suppliers

The approval of Sun Pharma Canada's generic Clobetasol Propionate 0.05% Topical Spray fundamentally alters the competitive landscape for this widely used topical corticosteroid. While specific alternative suppliers are not detailed in the available intelligence, the introduction of a new generic competitor from a prominent pharmaceutical entity like Sun Pharmaceutical Industries, Inc. means that all incumbent suppliers of Clobetasol Propionate will face heightened competition. This is particularly relevant for procurement directors seeking to diversify their supplier base and mitigate risks associated with single-source reliance. The market for Clobetasol Propionate, identified by its UNII 779619577M, will now see an additional player vying for contracts, offering an enhanced negotiating position for buyers. Regulatory affairs heads should monitor any subsequent ANDA filings for Clobetasol Propionate, as further generic entries would intensify this competitive pressure even further. Business development executives must now differentiate their Clobetasol Propionate offerings beyond price, focusing on supply reliability, customer service, and value-added services to retain and attract market share in an increasingly crowded field.

API Supply Chain Positioning for Clobetasol Propionate

The market entry of Sun Pharma Canada's generic Clobetasol Propionate 0.05% Topical Spray carries significant implications for the Active Pharmaceutical Ingredient (API) supply chain. With a new manufacturer entering the finished dosage form market, there is an increased demand for Clobetasol Propionate API. For procurement directors, this presents both opportunities and challenges. On one hand, the diversification of finished product suppliers can lead to a more robust and resilient supply chain for the end-user. On the other hand, it may create increased demand for the underlying API, potentially influencing global API pricing and availability. Supply chain VPs must assess their current API sourcing strategies for Clobetasol Propionate, ensuring that their existing suppliers can meet potential increases in demand or that alternative API sources are identified and qualified. Quality assurance teams must rigorously vet any new API suppliers that emerge to support this expanded generic market, adhering to stringent regulatory standards. Proactive engagement with API manufacturers is crucial to secure long-term supply and maintain cost efficiencies in this evolving market segment.

Procurement Implications and Timing for Clobetasol Propionate Sourcing

The approval of Sun Pharma Canada's generic Clobetasol Propionate 0.05% Topical Spray on March 26, 2018, necessitates immediate action from procurement and supply chain leadership. Procurement directors should swiftly initiate engagement with Sun Pharma Canada to explore supply agreements for ANDA208842. This proactive approach can secure favorable pricing and ensure early access to the new generic option, which is crucial for managing pharmaceutical expenditures. Supply chain VPs should review existing inventory levels and contract terms for Clobetasol Propionate to prepare for the anticipated market shift and potential price adjustments. The 'STANDARD' review priority for this ANDA suggests a typical market entry timeline post-approval, allowing for strategic planning rather than reactive measures. Furthermore, the broader industry context, including discussions among EU nations regarding unified drug pricing strategies, underscores a global trend towards cost containment, making generic approvals like this increasingly impactful. Companies that quickly adapt their procurement strategies to integrate new generic options will gain a significant competitive advantage in managing their cost base for essential dermatological treatments.

ChemLifeIntel analysis · Priya Subramaniam. Compiled from primary and reported sources.
CHEMLIFEINTEL TERMINAL

Go deeper than the brief

The Terminal adds the full entity graph behind this story — downstream buyer-exposure mapping, alternative-supplier shortlists, 5-year compliance footprints and live supply-chain risk scores. Built for procurement, regulatory and business-development teams.

TERMINAL ACCESS
Request Terminal Access

Tell us where to send your access details — used by procurement and regulatory teams at 40+ pharmaceutical companies.

Used by procurement and regulatory teams at 40+ pharmaceutical companies
CONNECTED COVERAGE

Related Intelligence

REGULATORY INTELLIGENCE
35 min ago

Pfizer's VIRACEPT Recall: Critical Labeling Error Exposes Supply Chain Vulnerabilities

Pfizer Inc. initiated a Class III recall for VIRACEPT (nelfinavir mesylate) tablets due to incorrect expiry labeling. Bottles specified 11/2016, while the correct date was 09/2016. This event, terminated in 2015, underscores critical supply chain and regulatory risks associated with quality control failures, impacting procurement and patient safety.

REGULATORY INTELLIGENCE
35 min ago

Albek De Mexico Hand Sanitizer Recall: Critical CGMP Deviations and Methanol Contamination Threaten Supply Chains

Albek De Mexico S.A. De C.V. initiated a Class II recall (D-0080-2021) for 27,000 bottles of hand sanitizer due to critical CGMP deviations, including sub-potent ethanol and methanol contamination. This event from their San Juan Del Rio, Mexico facility highlights significant quality control failures, posing immediate supply chain and regulatory compliance risks for procurement and regulatory affairs teams sourcing from the region.

REGULATORY INTELLIGENCE
35 min ago

Pharm D Solutions' Trimix QM10 Injectable Recalled Nationwide Over Sterility Concerns

Pharm D Solutions, LLC initiated a Class II recall of its Trimix QM10 Papaverine/Phentolamine/Atropine/PGE Injectable due to a lack of sterility assurance. This nationwide recall, involving 9 vials, underscores critical risks in compounded sterile products. Procurement and regulatory teams must scrutinize compounding pharmacy quality systems to mitigate supply chain vulnerabilities and ensure patient safety from such high-risk injectables.

REGULATORY INTELLIGENCE
35 min ago

FDA Class II Recall: ProRx LLC's Semaglutide Injection Faces Sterility Assurance Deficiencies

ProRx LLC has initiated a Class II recall for 8,400 vials of Semaglutide Injection due to a lack of sterility assurance. This event, originating from their Exton, PA facility, impacts distribution in Texas and Utah, demanding immediate attention from procurement and regulatory teams to mitigate supply chain risks and ensure patient safety.

REGULATORY INTELLIGENCE
35 min ago

Perrigo's Oxymetazoline HCl Recall Highlights Critical Excipient Quality Failures

Perrigo Company PLC's Class II recall of Oxymetazoline HCl 0.05% Nasal Decongestant due to a contaminated excipient underscores critical CGMP compliance risks. This event, initiated in October 2021, impacts procurement and supply chain strategies, demanding rigorous supplier qualification and robust quality agreements to mitigate similar disruptions and safeguard product integrity across the pharmaceutical sector.

REGULATORY INTELLIGENCE
35 min ago

FDA Class II Recall: Teva Pharmaceuticals USA Pulls Mixed Amphetamine Salts Due to Strength Discrepancies

Teva Pharmaceuticals USA initiated a Class II recall (D-1285-2020) of 33,280 bottles of mixed amphetamine salts tablets due to mixed strengths. This event, terminated by the FDA, highlights critical quality control challenges for procurement and regulatory teams, necessitating rigorous supplier oversight for controlled substances and ensuring supply chain resilience.

REGULATORY INTELLIGENCE
35 min ago

AmeriSource Bergen Faces FDA Class II Recall for Ifosfamide Due to Cold Chain Breach

AmeriSource Bergen initiated a Class II recall for 60 vials of Pfizer's Ifosfamide Injection 3g/60 mL due to temperature abuse at its distribution centers in Chesterbrook, PA. This nationwide voluntary recall, D-1066-2013, highlights critical vulnerabilities in cold chain management for oncology drugs. Procurement and regulatory teams must scrutinize distributor compliance to prevent compromised product efficacy and patient safety risks, reinforcing the need for robust quality agreements.

REGULATORY INTELLIGENCE
35 min ago

FDA Class II Recall: Little Moon Essentials' Crampy Belly Rub Faces Scrutiny Over CGMP Deviations and Labeling

Little Moon Essentials LLC has initiated a Class II recall for 788 units of Crampy Belly Rub (Camphor 1.1%) due to critical CGMP deviations and missing expiration dates. This action by the Dania Beach, FL-based firm highlights significant quality control failures, posing immediate risks to brand reputation and market access for procurement and regulatory teams in the global chemical and life sciences industry.

REGULATORY INTELLIGENCE
2h ago

SonoThera Secures $125M Series B Funding: No FDA Import Alert Information Available

The provided source text details SonoThera's successful $125 million Series B funding round, backed by major pharma entities. Crucially, the source contains no information regarding any FDA Import Alert, regulatory action, facility issues, or product detentions, making an analysis of such an event impossible based on the given data.

REGULATORY INTELLIGENCE
2h ago

FDA Class II Recall: Essential Wellness Pharma's Progesterone Injection Fails Sterility Assurance

Kalman Health & Wellness, Inc. dba Essential Wellness Pharma initiated a Class II recall for its Progesterone 100 mg/mL in Corn Oil Injection due to a critical lack of sterility assurance. This 2015 nationwide recall, terminated in 2017, stemmed from poor sterile production practices at its Peoria, IL facility. For procurement and regulatory leaders, this highlights the severe risks associated with compounded sterile preparations and underscores the imperative for rigorous supplier qualification and ongoing oversight in this sector.

CLINICAL & PIPELINE
2h ago

Trump Administration Floats Permanent Medicare Drug Price Negotiation Framework

The Trump administration proposes a permanent framework for Medicare drug price negotiations, leveraging the Inflation Reduction Act. This signals enduring pressure on pharmaceutical pricing, necessitating proactive strategic adjustments for procurement, regulatory affairs, and business development executives to mitigate revenue impacts and ensure market access.

CLINICAL & PIPELINE
2h ago

India's CDSCO Updates COVID-19 Vaccine Approvals Amidst Key Regulatory Shifts for Animal Health and GLP-1 Drugs

India's regulatory authority has updated its list of approved COVID-19 vaccines as of April 22, 2026, signaling ongoing public health oversight. Concurrently, new prohibitions on Chloramphenicol and Nitrofurans in food-producing animals, alongside strengthened enforcement for GLP-1 based drugs, underscore a tightening regulatory environment. Businesses must adapt supply chains and compliance strategies to these evolving mandates.

CLINICAL & PIPELINE
2h ago

Akeso Initiates Phase Ib/II Trial for AK138D1 in Advanced Breast Cancer, Signaling ADC Pipeline Expansion

Akeso has initiated a Phase Ib/II trial (AK138D1-202) for its HER3-targeting ADC, AK138D1, in advanced breast cancer, including HR+/HER2- and triple-negative subtypes. This early-stage development signals Akeso's strategic focus on novel oncology mechanisms, potentially impacting future procurement strategies for advanced biologics and competitive dynamics in the breast cancer therapeutic landscape. Decision-makers should monitor trial progression for market entry implications.

CLINICAL & PIPELINE
2h ago

Torrent Pharmaceuticals Secures US FDA ANDA Approval for Generic Lenalidomide Capsules, Reshaping Market Dynamics

Torrent Pharmaceuticals has received US FDA approval for its generic Lenalidomide capsules (ANDA213405). This significant development introduces a new competitor for a critical oncology molecule, offering procurement directors opportunities for cost reduction and supply chain diversification. Regulatory affairs and business development teams must assess the implications of this market entry, particularly concerning the existing REMS program.

TRADE & SUPPLY CHAIN
2h ago

FDA Reports Widespread Drug Shortages and Discontinuations Impacting Critical Care, Oncology, and CNS Therapies

The FDA's latest report reveals extensive drug shortages and discontinuations across critical therapeutic areas, including oncology, critical care, and CNS. This necessitates immediate strategic adjustments for procurement directors and supply chain VPs to mitigate supply chain vulnerabilities, manage pricing volatility, and ensure patient access to essential medications amidst a complex regulatory landscape.

REGULATORY INTELLIGENCE
2h ago

CDSCO Intensifies Regulatory Scrutiny: Implications for India's Pharma and MedTech Supply Chains

CDSCO's recent flurry of alerts, including drug theft, falsified medicines, and product recalls, signals heightened regulatory vigilance across India's pharmaceutical and medical device sectors. This demands robust supply chain security, stringent quality controls, and agile regulatory compliance from global and domestic players. Procurement, regulatory, and supply chain leaders must proactively adapt to mitigate risks and ensure market access.

REGULATORY INTELLIGENCE
3h ago

FDA Hearing Puts Amgen's Tavneos Market Future at Risk Amid Independent Data Review

Amgen faces a critical FDA hearing for its rare disease treatment, Tavneos, following an independent data review. This event could lead to market removal, demanding immediate risk assessment for procurement, supply chain, and regulatory teams. It underscores the FDA's intensified scrutiny on post-market data integrity and product efficacy.

REGULATORY INTELLIGENCE
3h ago

Takeda's TYK2 Inhibitor Victory Reshapes Plaque Psoriasis Market Dynamics

Takeda has secured a significant competitive advantage in the TYK2 inhibitor landscape, outperforming Bristol Myers Squibb’s Sotyktu. This victory positions Takeda strongly for its anticipated plaque psoriasis launch next year, signaling a material shift in market share and procurement strategies for dermatology portfolios. Decision-makers must reassess existing supply agreements and future market entrants.

REGULATORY INTELLIGENCE
4h ago

Genentech Restructures gRED Leadership, Signals R&D Strategic Shift

Genentech, a Roche subsidiary, is undergoing a significant restructuring within its Research and Early Development (gRED) group in South San Francisco, affecting key Vice Presidents. This move signals a strategic re-evaluation of early-stage pipeline priorities, impacting future drug development and commercial opportunities for biopharma stakeholders. The total number of affected positions remains undisclosed.

REGULATORY INTELLIGENCE
4h ago

Teva Pharmaceuticals Restructures API Unit: 250 Layoffs and Divestiture Signals Strategic Pivot

Teva Pharmaceuticals is implementing significant restructuring, including 250 layoffs at its Neot Hovav, Israel API unit, TAPI, as it seeks a buyer. This divestiture, part of a broader $700 million savings initiative, signals Teva's strategic pivot towards innovative brands like Austedo and Ajovy. Supply chain and procurement leaders must assess potential API sourcing shifts and geopolitical risks impacting Teva's operational stability and future supply agreements.

CLINICAL & PIPELINE
4h ago

EU Nations Push for Unified Drug Pricing Strategy Amid US Pressure: Key Implications for Pharma

Belgium, Netherlands, Luxembourg, Austria, and Ireland's June 10 statement signals a coordinated EU response to drug pricing pressure from the U.S. This move demands immediate attention from procurement directors and regulatory affairs heads, indicating potential shifts towards unified European pharmaceutical procurement and market access frameworks, impacting future commercial strategies across the Union.

REGULATORY INTELLIGENCE
4h ago

Astellas Implements $1.3 Billion Cost-Savings Program Ahead of Xtandi Patent Cliff

Astellas is implementing a 200 billion yen ($1.3 billion) cost-savings program over five years to mitigate a projected $6 billion revenue decline from its prostate cancer drug Xtandi's patent expiration. This strategic initiative, as stated by CEO Naoki Okamura, extends beyond mere cost or headcount reductions, signaling a broader operational recalibration for the global pharmaceutical firm.

ENTITY HUBS

Entities in this Brief

HK Kolmar Canada
company hub
Open company hub
Clobetasol Propionate
molecule hub
Open molecule hub